Form 4: Janux Therapeutics Officer Tighe Reardon Reports Stock Sales
SEC Form 4
Tighe Reardon, Acting Chief Financial Officer of Janux Therapeutics, reports the sale of common stock held indirectly through Avalon BioVentures.
Summary
- On June 3, 2024, Tighe Reardon, Acting Chief Financial Officer of Janux Therapeutics, reported the sale of 131,196 shares of common stock at a price of $54.75.
- An additional 691,525 shares were sold at the same price on the same day.
- These shares were held indirectly through Avalon BioVentures I, LP and Avalon BioVentures SPV I, L.P.
- Following these transactions, Reardon directly owns 174,989 shares and indirectly owns 633,673 shares through Avalon BioVentures I, LP and 3,340,018 shares through Avalon BioVentures SPV I, L.P.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock sales by an officer. The impact depends on the reasons for the sale and the overall market context.
Industry Context
Form 4 filings are standard disclosures required by the SEC when corporate insiders buy or sell their company's stock. They provide transparency into the transactions of individuals with access to non-public information.
Stakeholder Impact
- Shareholders may react to the news of insider selling, depending on the size of the transaction and the perceived reasons behind it.
Key Dates
| Date | Description |
|---|---|
| 06/03/2024 | Date of stock sale transactions |
| 06/05/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.